The excitement around Moderna's cancer vaccine is cooling. Here's why.
Bristol-Myers Squibb Co BMY
News
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study
Tempus AI Expands Bristol Myers Partnership With Multi-Year Oncology, AI Data Deals
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions
Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study
Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
Advancing Access to Lung Cancer Care Through Artificial Intelligence Innovation
Bristol Myers Squibb Treatment Meets Primary Endpoint in Phase 3 Trial for Idiopathic Pulmonary Fibrosis
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
Bristol Myers Squibb Says FDA Approves Heart Disease Treatment Camzyos for Pediatric Patients
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
Care Within Reach: How the Bristol Myers Squibb Foundation Is Strengthening Health Systems Across Africa
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Leveraging Brazil's Health Networks for Early Lung Cancer Detection
United States